A 38-year-old woman with newly diagnosed systemic lupus erythematosus (SLE) presents with mild-to-moderate disease activity (arthritis, rash, no renal or CNS involvement). She requires corticosteroid therapy for immunosuppression. Which corticosteroid is the drug of choice for long-term maintenance therapy in SLE?

Explanation

## Corticosteroid Selection in SLE **Key Point:** Prednisolone is the gold standard corticosteroid for long-term management of SLE because it offers the optimal balance of glucocorticoid potency, mineralocorticoid activity, and a duration of action suitable for once-daily dosing. ### Why Prednisolone is Preferred 1. **Intermediate duration of action** (12–36 hours) — allows once-daily dosing, improving compliance and reducing HPA axis suppression compared to longer-acting agents. 2. **Physiologic mineralocorticoid activity** — maintains sodium and fluid balance better than purely synthetic agents; important in chronic therapy. 3. **Established safety profile** — decades of use in autoimmune diseases with well-characterized dose-response relationships and long-term side-effect data. 4. **Dose flexibility** — can be titrated from low maintenance doses (5–10 mg/day) to higher induction doses (0.5–1 mg/kg/day) without loss of efficacy. ### Comparison with Other Options | Agent | Duration | Potency | Mineralocorticoid | Use in SLE | |-------|----------|---------|-------------------|------------| | **Prednisolone** | 12–36 hrs | 4× | Yes (physiologic) | **First-line, maintenance** | | Dexamethasone | 36–72 hrs | 25–30× | Minimal | Acute exacerbations, cerebritis only | | Methylprednisolone | 12–36 hrs | 5× | Minimal | IV pulse therapy (exacerbations) | | Betamethasone | 36–72 hrs | 25× | Minimal | Not used in SLE | **High-Yield:** Prednisolone is preferred over dexamethasone and betamethasone for chronic SLE because the longer duration of action of these synthetic agents causes greater HPA suppression and increased risk of osteoporosis with prolonged use. Methylprednisolone is reserved for IV pulse therapy in severe flares. **Clinical Pearl:** In SLE, the goal is to use the **lowest effective dose** of prednisolone (typically 5–20 mg/day) because cumulative corticosteroid exposure is the primary driver of long-term complications (infections, osteoporosis, avascular necrosis). **Warning:** ~~Dexamethasone~~ is NOT suitable for long-term SLE therapy due to its very long half-life and minimal mineralocorticoid activity, leading to excessive HPA suppression and electrolyte disturbances.